Efficacy and safety of high dose recombinant human thrombopoietin in the treatment of immune thrombocytopenia
Platelets. 2023 Dec;34(1):2271568. doi: 10.1080/09537104.2023.2271568. Epub 2023 Nov 8.ABSTRACTThe conventional dose of recombinant human thrombopoietin (rhTPO) in the treatment of immune thrombocytopenia (ITP) is 300 U/kg per day, but the clinical reaction rate is not satisfactory. Accordingly, we explored the efficacy and safety of increasing rhTPO dose in the treatment of ITP. A retrospective study was conducted to collect the clinical data of 105 ITP patients who were divided into two groups, a low-dose group (15 000 U/day) and a high-dose group (30 000 U/day) according to the dose of rhTPO. The total effective rate of...
Source: Platelets - November 9, 2023 Category: Hematology Authors: Xiuli Wang Hui Bi Lin Liu Yuebo Liu Liefen Yin Jin Yao Jingxing Yu Wei Tao Yueping Wei Yu Li Lingmei Yin Hongli Mu Yadong Du Zeping Zhou Source Type: research
Genetic background of thrombocytosis in mice mimicking hereditary thrombocytosis in humans
Platelets. 2023 Dec;34(1):2276697. doi: 10.1080/09537104.2023.2276697. Epub 2023 Nov 9.NO ABSTRACTPMID:37941443 | DOI:10.1080/09537104.2023.2276697 (Source: Platelets)
Source: Platelets - November 9, 2023 Category: Hematology Authors: Hiroyuki Kimura Masahiro Onozawa Takanori Teshima Source Type: research
Efficacy and safety of high dose recombinant human thrombopoietin in the treatment of immune thrombocytopenia
Platelets. 2023 Dec;34(1):2271568. doi: 10.1080/09537104.2023.2271568. Epub 2023 Nov 8.ABSTRACTThe conventional dose of recombinant human thrombopoietin (rhTPO) in the treatment of immune thrombocytopenia (ITP) is 300 U/kg per day, but the clinical reaction rate is not satisfactory. Accordingly, we explored the efficacy and safety of increasing rhTPO dose in the treatment of ITP. A retrospective study was conducted to collect the clinical data of 105 ITP patients who were divided into two groups, a low-dose group (15 000 U/day) and a high-dose group (30 000 U/day) according to the dose of rhTPO. The total effective rate of...
Source: Platelets - November 9, 2023 Category: Hematology Authors: Xiuli Wang Hui Bi Lin Liu Yuebo Liu Liefen Yin Jin Yao Jingxing Yu Wei Tao Yueping Wei Yu Li Lingmei Yin Hongli Mu Yadong Du Zeping Zhou Source Type: research
Genetic background of thrombocytosis in mice mimicking hereditary thrombocytosis in humans
Platelets. 2023 Dec;34(1):2276697. doi: 10.1080/09537104.2023.2276697. Epub 2023 Nov 9.NO ABSTRACTPMID:37941443 | DOI:10.1080/09537104.2023.2276697 (Source: Platelets)
Source: Platelets - November 9, 2023 Category: Hematology Authors: Hiroyuki Kimura Masahiro Onozawa Takanori Teshima Source Type: research
Efficacy and safety of high dose recombinant human thrombopoietin in the treatment of immune thrombocytopenia
Platelets. 2023 Dec;34(1):2271568. doi: 10.1080/09537104.2023.2271568. Epub 2023 Nov 8.ABSTRACTThe conventional dose of recombinant human thrombopoietin (rhTPO) in the treatment of immune thrombocytopenia (ITP) is 300 U/kg per day, but the clinical reaction rate is not satisfactory. Accordingly, we explored the efficacy and safety of increasing rhTPO dose in the treatment of ITP. A retrospective study was conducted to collect the clinical data of 105 ITP patients who were divided into two groups, a low-dose group (15 000 U/day) and a high-dose group (30 000 U/day) according to the dose of rhTPO. The total effective rate of...
Source: Platelets - November 9, 2023 Category: Hematology Authors: Xiuli Wang Hui Bi Lin Liu Yuebo Liu Liefen Yin Jin Yao Jingxing Yu Wei Tao Yueping Wei Yu Li Lingmei Yin Hongli Mu Yadong Du Zeping Zhou Source Type: research
Genetic background of thrombocytosis in mice mimicking hereditary thrombocytosis in humans
Platelets. 2023 Dec;34(1):2276697. doi: 10.1080/09537104.2023.2276697. Epub 2023 Nov 9.NO ABSTRACTPMID:37941443 | DOI:10.1080/09537104.2023.2276697 (Source: Platelets)
Source: Platelets - November 9, 2023 Category: Hematology Authors: Hiroyuki Kimura Masahiro Onozawa Takanori Teshima Source Type: research
Efficacy and safety of high dose recombinant human thrombopoietin in the treatment of immune thrombocytopenia
Platelets. 2023 Dec;34(1):2271568. doi: 10.1080/09537104.2023.2271568. Epub 2023 Nov 8.ABSTRACTThe conventional dose of recombinant human thrombopoietin (rhTPO) in the treatment of immune thrombocytopenia (ITP) is 300 U/kg per day, but the clinical reaction rate is not satisfactory. Accordingly, we explored the efficacy and safety of increasing rhTPO dose in the treatment of ITP. A retrospective study was conducted to collect the clinical data of 105 ITP patients who were divided into two groups, a low-dose group (15 000 U/day) and a high-dose group (30 000 U/day) according to the dose of rhTPO. The total effective rate of...
Source: Platelets - November 9, 2023 Category: Hematology Authors: Xiuli Wang Hui Bi Lin Liu Yuebo Liu Liefen Yin Jin Yao Jingxing Yu Wei Tao Yueping Wei Yu Li Lingmei Yin Hongli Mu Yadong Du Zeping Zhou Source Type: research
Genetic background of thrombocytosis in mice mimicking hereditary thrombocytosis in humans
Platelets. 2023 Dec;34(1):2276697. doi: 10.1080/09537104.2023.2276697. Epub 2023 Nov 9.NO ABSTRACTPMID:37941443 | DOI:10.1080/09537104.2023.2276697 (Source: Platelets)
Source: Platelets - November 9, 2023 Category: Hematology Authors: Hiroyuki Kimura Masahiro Onozawa Takanori Teshima Source Type: research
Efficacy and safety of high dose recombinant human thrombopoietin in the treatment of immune thrombocytopenia
Platelets. 2023 Dec;34(1):2271568. doi: 10.1080/09537104.2023.2271568. Epub 2023 Nov 8.ABSTRACTThe conventional dose of recombinant human thrombopoietin (rhTPO) in the treatment of immune thrombocytopenia (ITP) is 300 U/kg per day, but the clinical reaction rate is not satisfactory. Accordingly, we explored the efficacy and safety of increasing rhTPO dose in the treatment of ITP. A retrospective study was conducted to collect the clinical data of 105 ITP patients who were divided into two groups, a low-dose group (15 000 U/day) and a high-dose group (30 000 U/day) according to the dose of rhTPO. The total effective rate of...
Source: Platelets - November 9, 2023 Category: Hematology Authors: Xiuli Wang Hui Bi Lin Liu Yuebo Liu Liefen Yin Jin Yao Jingxing Yu Wei Tao Yueping Wei Yu Li Lingmei Yin Hongli Mu Yadong Du Zeping Zhou Source Type: research
Genetic background of thrombocytosis in mice mimicking hereditary thrombocytosis in humans
Platelets. 2023 Dec;34(1):2276697. doi: 10.1080/09537104.2023.2276697. Epub 2023 Nov 9.NO ABSTRACTPMID:37941443 | DOI:10.1080/09537104.2023.2276697 (Source: Platelets)
Source: Platelets - November 9, 2023 Category: Hematology Authors: Hiroyuki Kimura Masahiro Onozawa Takanori Teshima Source Type: research
Deep learning, 3D ultrastructural analysis reveals quantitative differences in platelet and organelle packing in COVID-19/SARSCoV2 patient-derived platelets
Platelets. 2023 Dec;34(1):2264978. doi: 10.1080/09537104.2023.2264978. Epub 2023 Nov 7.ABSTRACTPlatelets contribute to COVID-19 clinical manifestations, of which microclotting in the pulmonary vasculature has been a prominent symptom. To investigate the potential diagnostic contributions of overall platelet morphology and their α-granules and mitochondria to the understanding of platelet hyperactivation and micro-clotting, we undertook a 3D ultrastructural approach. Because differences might be small, we used the high-contrast, high-resolution technique of focused ion beam scanning EM (FIB-SEM) and employed deep learning ...
Source: Platelets - November 7, 2023 Category: Hematology Authors: Sagar S Matharu Cassidy S Nordmann Kurtis R Ottman Rahul Akkem Douglas Palumbo Denzel R D Cruz Kenneth Campbell Gail Sievert Jamie Sturgill James Z Porterfield Smita Joshi Hammodah R Alfar Chi Peng Irina D Pokrovskaya Jeffrey A Kamykowski Jeremy P Wood Be Source Type: research
α-Synuclein is the major platelet isoform but is dispensable for activation, secretion, and thrombosis
In this study, immunofluorescence showed that α-synuclein was present on punctate structures that co-stained with markers for α-granules and lysosomes and in a cytoplasmic pool. We analyzed the phenotype of α-synuclein-/- mice and their platelets. Platelets from knockout mice had a mild, agonist-dependent secretion defect but aggregation and spreading in vitro were unaffected. Consistently, thrombosis/hemostasis were unaffected in the tail-bleeding, FeCl3 carotid injury and jugular vein puncture models. None of the platelet secretory machinery examined, e.g. the v-SNAREs, were affected by α-synuclein's loss. The result...
Source: Platelets - November 6, 2023 Category: Hematology Authors: Alexis N Smith Smita Joshi Harry Chanzu Hammodah R Alfar Kanakanagavalli Shravani Prakhya Sidney W Whiteheart Source Type: research
α-Synuclein is the major platelet isoform but is dispensable for activation, secretion, and thrombosis
In this study, immunofluorescence showed that α-synuclein was present on punctate structures that co-stained with markers for α-granules and lysosomes and in a cytoplasmic pool. We analyzed the phenotype of α-synuclein-/- mice and their platelets. Platelets from knockout mice had a mild, agonist-dependent secretion defect but aggregation and spreading in vitro were unaffected. Consistently, thrombosis/hemostasis were unaffected in the tail-bleeding, FeCl3 carotid injury and jugular vein puncture models. None of the platelet secretory machinery examined, e.g. the v-SNAREs, were affected by α-synuclein's loss. The result...
Source: Platelets - November 6, 2023 Category: Hematology Authors: Alexis N Smith Smita Joshi Harry Chanzu Hammodah R Alfar Kanakanagavalli Shravani Prakhya Sidney W Whiteheart Source Type: research
Humanized mouse models for inherited thrombocytopenia studies
This article mainly reviews the development of humanized mice models, the construction methods, research status, and problems of using humanized mice for the in vivo study of human thrombopoiesis.PMID:37849076 | DOI:10.1080/09537104.2023.2267676 (Source: Platelets)
Source: Platelets - October 18, 2023 Category: Hematology Authors: Xiaojie Wang Maoshan Chen Lanyue Hu Chengning Tan Xiaoliang Li Peipei Xue Yangzhou Jiang Peipei Bao Teng Yu Fengjie Li Yanni Xiao Qian Ran Zhongjun Li Li Chen Source Type: research
